Skip to main content

Table 6 Projected outcomes of six TB screening strategies for a cohort of 1000 healthcare workers: alternate scenario with confirmatory repeat interferon-gamma release assays (IGRAs) (use of two sequential positive IGRAs to identify candidates for treatment of LTBI)

From: Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis

Strategy Cost in 2015 $CAN QALYs New active TB cases Deaths due to active TB Deaths due to adverse event to treatment of active TB Deaths due to adverse event to treatment of LTBI True positive results False positive results
Post-exposure screening only
 Tuberculin SKIN Test $66,387 15,239.98 3.03 0.13 0.0023 0.00036 63 6
 QuantiFERON®-TB-Gold $77,521 15,239.85 2.97 0.13 0.0023 0.00040 67 11
Targeted screening
 Tuberculin Skin Test $151,517 15,237.96 2.83 0.12 0.0022 0.00093 67 109
 QuantiFERON®-TB-Gold $260,558 15,239.67 2.67 0.12 0.0020 0.00049 78 17
Annual screening
 Tuberculin Skin Test $404,956 15,231.85 2.68 0.12 0.0020 0.00258 75 413
 QuantiFERON®-TB-Gold $801,059 15,238.94 2.44 0.11 0.0019 0.00072 93 46
  1. TB tuberculosis, QALYS quality-adjusted life years, LTBI latent tuberculosis infection